Amgen, Inc. (NASDAQ:AMGN) Migraine Treatment Drug Passes Phase 2 Trials

In a breakthrough in migraine treatment, the Phase 2 results of the clinical trials of AMG 334 drug by Amgen, Inc. (NASDAQ:AMGN) has been successful. Competing with the existing migraine drugs, the monthly rates of migraine attacks were comparably less when using this medication. According to the company, the AMG 334 drug lowered the chance […]

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) Looks To Save Costs, After Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Pulled Out

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) opted out of the collaboration with OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI). The latter based out of Seattle and the exit in partnership took place after giving out $23 million. The two entities won’t be together anymore in developing drug custirsen for fighting out late stage occurrences of cancer. Share-Sellout The […]

Mylan NV (NASDAQ:MYL) Rejects Teva-Takeover, Calls The Bid Undervalued

Global pharmaceutical company Mylan NV (NASDAQ:MYL) chose to reject the unsolicited buyout bid by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). The decision was made unanimously by the current Board of Directors. Teva Undervalued Mylan The opinionated directors believe that the bid approached by Teva authorities was lackluster, in all regards. The price quoted for Mylan […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Gears To Comply With Regulatory Requirements To Acquire Mylan NV (NASDAQ:MYL)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday announced plans to sell some of its operations that are necessary to meet regulatory formalities to purchase its competitor Mylan NV (NASDAQ:MYL). Teva Pharmaceutical has not revealed the details of operations that are put on sale for the possible acquisition. In a bid to reduce pressure for […]

Mylan NV (NASDAQ:MYL) – Immediate Support At $66 Keeps The Bulls In Control

Mylan NV (NASDAQ:MYL) opened up with a big gap of over 9% and managed to end the session with almost all the gains protected after registering a new lifetime high at $74.90. The volume surged to 42 million against the daily average of 15 million only. This spurt in both price and volume was inspired […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Pitches For Mylan For $40 bn

Much to the chagrin of the global pharmaceutical trade, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) made known its intent to acquire its rival, Mylan NV (NASDAQ:MYL) for $40 billion. The deal comes on the back of weeks of speculation that Teva would offer a buyout for Mylan. Touted to be the largest deal of the […]

AbbVie Inc. (NYSE:ABBV) Accused of Colluding with Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to Bar Generic Drug Development

Boston, MA 09/09/2014 (wallstreetpr) – AbbVie Inc. (NYSE:ABBV) is gearing up for a legal battle with the U.S. Federal Trade Commission after being accused of barring the development of generic versions of AndroGel according to Reuters. AndroGel One of the Top Selling drugs AndroGel is a pill specifically developed to be used by men with […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) – Nuvigil Patent Infringement Lawsuit Resolved

Boston, MA 06/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) continues to file a series of patent infringement lawsuits against various company as it seeks to protect its products from generic competition. It goes without saying that some of these cases result in unnecessary expenses, prompting companies to opt for early settlement as it […]

JP Morgan Confident About Bristol-Myers Squibb Co (NYSE:BMY)

Boston, MA 06/17/2014 (wallstreetpr) – Despite the news of loosing the legal battle to Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), JP Morgan sees strength in Bristol-Myers Squibb Co (NYSE:BMY), which suggests it to buy on pullback. Recently, the company reported that the U.S. Court of Appeals has upheld the District court’s ruling relating to the […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Acquires Drug That Could Fetch $3 Billion In Sales

Boston, MA 06/04/2014 (wallstreetpr) – Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is pulling all stops in efforts to improve financial performance for the long-haul. In addition to internal adjustments, the company is also in the lookout for acquisition opportunities. And in the latest case the company announced the acquisition of Labrys Biologics, a startup […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA): The Time To Sell

Boston, MA 06/03/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is trading near its 52 week high. Seeing the present conditions linked with Copaxone, it is wise to sell the stock or have some cushion by buying the put options. Goldman has warned of a sell off on Teva due to the problems associated […]

Competition Stricken Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) May Look For India Deal Despite Denial

Boston, MA 05/23/2014 (wallstreetpr) – The Israel-based drug company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has taken several doses of its own medicine in recent times. The company that thrives in developing and marketing generic drugs has in recent times until last week tried to stop competitors from developing a copycat of its bestselling Copaxone […]

Why Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Is The Bold But Not The Beautiful

Boston, MA 05/22/2014 (wallstreetpr) – Drug companies are in high-activity mode around the world. While some like Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) are working hard to block generic competitors, others like Pfizer Inc (NYSE:PFE) are seeking deals to join forces with promising peers. It is all about actions and counter actions in the global pharmaceutical […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Patent Problems:

Boston, MA 04/23/2014 (wallstreetpr)  – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is an Israel-based drug company. The generic drug companies are giving TEVA a tough competition. The generic companies are developing a cheaper version of the blockbuster drug by TEVA called Copaxone. Teva is trying its best to stop the generic companies from developing the cheaper […]

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Could Recover Infringement Damages

Boston, MA 04/22/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is a $48 billion Israel-based drug company. The company is facing possible competition from generic drug manufacturers that are vying to develop generic version of its blockbuster drug, Copaxone. Efforts by the company to block generic manufacturers from developing cheaper versions of the drug have […]